1 Introduction Finerenone, a non-steroidal mineralocorticoid receptor antagonist, is indicated to slow kidney disease progression for patients with chronic kidney disease (CKD) and type 2 diabetes (T2DM) [1, 2] and to reduce cardiovascular outcomes among patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≥ 40% [3].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Thomas Eissing
Response to: ‘Comment on: ‘Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist”
Dear Editor, We thank Dr Fernández Ferreiro, Dr Mangas-Sanuan and Dr del Amo for their interest in our article titled “Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.” This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 18 print issues and online access $259.00 per year only $14.39 per issue Buy this article Purchase on SpringerLink...
Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist
Abstract Intravitreal (IVT) anti–vascular endothelial growth factor (anti-VEGF) therapies are the standard of care for retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Despite the favourable efficacy and safety profiles of these therapies, decreasing the treatment burden is still an unmet need because frequent injections may be required over many years.
Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data
1 Introduction Exposure-response (ER) and pharmacokinetic-pharmacodynamic analyses can support dose selection. Dose selection questions are inherently causal in nature: “how would the outcome of a patient (or a group of patients) change with dose level X versus dose level Y versus no treatment?” [1]. Accurate answers to these questions therefore rely on unbiased estimates of the causal and pharmacological relationship between drug exposure and response [2, 3].
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Thomas
Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack